Staphylokinase for intermediate high-risk pulmonary embolism
Part of Heart & circulation, Lungs & breathing clinical trials.
This trial tests a new drug, staphylokinase, to see if it can break up blood clots in the lungs in people with a moderate-high risk pulmonary embolism. The goal is to improve blood flow and reduce the chance of complications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a confirmed pulmonary embolism (blood clot in your lungs) with moderate-high risk, diagnosed within the last 2 weeks.
- Imaging shows the clot is causing strain on the right side of your heart.
- You have signs of possible instability, like low blood pressure, fast breathing, low oxygen, or heart failure.
- You have an elevated level of a heart enzyme called troponin I in your blood.
- You agree to use reliable birth control during the study and for 3 weeks after (if applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment that uses ultrasound to guide a thin tube (catheter) to deliver clot-busting medicine directly into the blood clot in your lung. It may be an option for people whose clot is serious but not yet causing shock, and who have symptoms that started within the last two weeks.
This trial compares three treatments for an intermediate-high risk pulmonary embolism: a minimally invasive clot removal procedure (embolectomy), a low-dose clot-dissolving medication, or standard blood thinning (heparin). The goal is to see which approach works best to prevent worsening while reducing bleeding risks.
This study compares different real-world treatments for a serious but stable type of blood clot in the lungs (called intermediate-high risk pulmonary embolism). It aims to see which treatments work best in everyday patients, including those with other health conditions.
This Phase 3 trial tests a catheter-based procedure to remove a lung blood clot (pulmonary embolism) and reduce strain on the heart. It may help people who have specific CT scan signs of right-heart strain.
This study tests a new way of delivering a clot-dissolving medicine for people with a serious but not immediately life-threatening pulmonary embolism. The goal is to see if giving the medicine as small bursts directly into the clot can help the heart recover faster.
This trial tests a device called the FlowTriever to remove blood clots from the lungs in people with a pulmonary embolism that is not too severe. The goal is to see if this treatment can help improve heart function and symptoms without major surgery.
Hear when a new Pulmonary Embolism trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.